SK281405B6 - Terapeutický prípravok na transdermálnu aplikáciu účinných látok - Google Patents
Terapeutický prípravok na transdermálnu aplikáciu účinných látok Download PDFInfo
- Publication number
- SK281405B6 SK281405B6 SK558-98A SK55898A SK281405B6 SK 281405 B6 SK281405 B6 SK 281405B6 SK 55898 A SK55898 A SK 55898A SK 281405 B6 SK281405 B6 SK 281405B6
- Authority
- SK
- Slovakia
- Prior art keywords
- active substances
- skin
- hmg
- increase
- therapeutic preparation
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 10
- 239000013543 active substance Substances 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract description 3
- 238000010521 absorption reaction Methods 0.000 claims abstract description 9
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims abstract description 7
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims abstract description 7
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims abstract description 7
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 7
- 229960004844 lovastatin Drugs 0.000 claims description 7
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 7
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 5
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 1
- 229950009116 mevastatin Drugs 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 11
- 239000004615 ingredient Substances 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 11
- 239000003524 antilipemic agent Substances 0.000 description 8
- 230000004888 barrier function Effects 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 231100000245 skin permeability Toxicity 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- -1 for example Chemical compound 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229950008325 levothyroxine Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003335 steric effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19541260A DE19541260A1 (de) | 1995-11-06 | 1995-11-06 | Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut |
| PCT/EP1996/004138 WO1997017061A1 (fr) | 1995-11-06 | 1996-09-21 | Preparation therapeutique pour l'administration transdermique de substances actives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK55898A3 SK55898A3 (en) | 1998-11-04 |
| SK281405B6 true SK281405B6 (sk) | 2001-03-12 |
Family
ID=7776710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK558-98A SK281405B6 (sk) | 1995-11-06 | 1996-09-21 | Terapeutický prípravok na transdermálnu aplikáciu účinných látok |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6379696B1 (fr) |
| EP (1) | EP0859595B1 (fr) |
| JP (1) | JP2001507331A (fr) |
| KR (1) | KR100445940B1 (fr) |
| CN (1) | CN1201385A (fr) |
| AT (1) | ATE186209T1 (fr) |
| AU (1) | AU716896B2 (fr) |
| CZ (1) | CZ289143B6 (fr) |
| DE (2) | DE19541260A1 (fr) |
| ES (1) | ES2141534T3 (fr) |
| GR (1) | GR3032523T3 (fr) |
| IL (1) | IL124279A (fr) |
| MX (1) | MX9803563A (fr) |
| MY (1) | MY132407A (fr) |
| NO (1) | NO982006L (fr) |
| NZ (1) | NZ318783A (fr) |
| PL (1) | PL326497A1 (fr) |
| PT (1) | PT859595E (fr) |
| SK (1) | SK281405B6 (fr) |
| WO (1) | WO1997017061A1 (fr) |
| ZA (1) | ZA969271B (fr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19830732B4 (de) * | 1998-07-09 | 2008-11-13 | Lts Lohmann Therapie-Systeme Ag | Zusammensetzung, enthaltend mindestens einen die Blutfettwerte beeinflussenden Wirkstoff und seine Verwendung |
| KR100764699B1 (ko) * | 2000-09-08 | 2007-10-08 | 알자 코포레이션 | 경로 폐쇄 저해에 의한 경피 약물 플럭스 감소 저해방법 |
| US20020187169A1 (en) * | 2001-05-11 | 2002-12-12 | Shoujun Chen | Kavalactone compositions |
| CA2534238A1 (fr) * | 2003-07-28 | 2005-02-10 | Alza Corporation | Systeme d'administration transdermique contenant de la warfarine |
| WO2005094814A1 (fr) * | 2004-03-31 | 2005-10-13 | Kowa Co., Ltd. | Préparation externe |
| JP2009534459A (ja) * | 2006-04-26 | 2009-09-24 | ローズモント・フアーマシユーテイカルズ・リミテツド | 液体経口組成物 |
| US7803778B2 (en) | 2006-05-23 | 2010-09-28 | Theracos, Inc. | Glucose transport inhibitors and methods of use |
| US7893053B2 (en) | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
| US8748419B2 (en) | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
| US7652767B2 (en) * | 2006-10-19 | 2010-01-26 | Sporian Microsystems, Inc. | Optical sensor with chemically reactive surface |
| US20080152592A1 (en) * | 2006-12-21 | 2008-06-26 | Bayer Healthcare Llc | Method of therapeutic drug monitoring |
| US20100210932A1 (en) * | 2007-03-20 | 2010-08-19 | Bayer Healthcare Llc | Method of analyzing an analyte |
| AU2008232419B2 (en) | 2007-04-02 | 2013-06-20 | Theracos, Inc. | Benzylic glycoside derivatives and methods of use |
| UA99924C2 (en) | 2007-08-23 | 2012-10-25 | Теракос, Инк. | Benzylbenzol derivatives and using thereof |
| TWI523652B (zh) | 2008-07-15 | 2016-03-01 | 泰瑞克公司 | 氘化苄基苯衍生物及使用方法 |
| SMT201600475T1 (it) | 2008-08-22 | 2017-03-08 | Theracos Sub Llc | Procedimenti per la preparazione di inibitori di sglt2. |
| ES2554375T3 (es) | 2008-11-25 | 2015-12-18 | University Of Rochester | Inhibidores de las MLK y métodos de uso |
| WO2010150100A1 (fr) | 2009-06-24 | 2010-12-29 | Entarco Sa | Utilisation de spinosynes et de compositions à base de spinosyne pour lutter contre des affections provoquées par des protozoaires, contes des infections virales et contre le cancer |
| WO2011130455A1 (fr) | 2010-04-13 | 2011-10-20 | Najib Babul | Compositions pharmaceutiques dermiques de 1-méthyl-2',6'-pipécoloxylidide et méthode d'utilisation |
| NZ603644A (en) | 2010-05-24 | 2014-10-31 | Univ Rochester | Bicyclic heteroaryl kinase inhibitors and methods of use |
| WO2011153712A1 (fr) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Forme cristalline d'inhibiteur de sglt2 de type benzyl-benzène |
| US20160184340A1 (en) | 2010-12-22 | 2016-06-30 | Christine Kritikou | The use of spinosyns and spinosyn compositions as local anesthetics and as antiarrhythmic agents |
| WO2012112933A1 (fr) | 2011-02-18 | 2012-08-23 | The Scripps Research Institute | Différenciation dirigée de cellules précurseurs d'oligodendrocytes vers un destin cellulaire myélinisant |
| EP2925319B1 (fr) | 2012-11-30 | 2019-01-09 | University Of Rochester | Inhibiteurs de kinase de lignage mixte pour des thérapies pour le vih/sida |
| US9420820B2 (en) | 2013-08-09 | 2016-08-23 | University Of Tsukuba | Method for isolating polyphenols from olive mill water |
| WO2015143240A2 (fr) | 2014-03-19 | 2015-09-24 | Curza Global, Llc | Compositions et procédés comprenant des 2- (acylamino) imidazoles |
| EP3601232B1 (fr) | 2017-03-31 | 2022-11-23 | Curza Global LLC | Compositions et procédés comprenant des 2-aminoimidazoles substitués |
| EP3841123A2 (fr) | 2018-08-23 | 2021-06-30 | Seagen Inc. | Anticorps anti-tigit |
| IL302402A (en) | 2020-11-08 | 2023-06-01 | Seagen Inc | Combination therapy |
| CA3216170A1 (fr) | 2021-04-09 | 2022-10-13 | Seagen Inc. | Methodes de traitement du cancer a l'aide d'anticorps anti-tigit |
| WO2024191807A1 (fr) | 2023-03-10 | 2024-09-19 | Seagen Inc. | Méthodes de traitement du cancer à l'aide d'anticorps anti-tigit |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3634016A1 (de) * | 1986-04-17 | 1987-10-29 | Lohmann Gmbh & Co Kg | Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung |
| US5211947A (en) * | 1988-12-16 | 1993-05-18 | Schering Corporation | Method for lowering blood cholesterol levels with granulocyte-macrophage colony stimulating factor |
| US5316765A (en) * | 1989-09-07 | 1994-05-31 | Karl Folkers Foundation For Biomedical And Clinical Research | Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies |
| ES2094809T3 (es) * | 1990-03-30 | 1997-02-01 | Yasunori Morimoto | Composicion absorbible por via percutanea del clorhidrato de morfina. |
| IL109037A (en) * | 1993-03-19 | 1999-01-26 | Cellegy Pharma Inc | Preparations for causing phase separation of lipid layers and preparation of the above preparations |
| DE4341444C2 (de) * | 1993-12-04 | 1996-03-14 | Lohmann Therapie Syst Lts | Wirkstoffhaltiges Pflaster und Verfahren zu seiner Herstellung |
| US5968983A (en) * | 1994-10-05 | 1999-10-19 | Nitrosystems, Inc | Method and formulation for treating vascular disease |
-
1995
- 1995-11-06 DE DE19541260A patent/DE19541260A1/de not_active Withdrawn
-
1996
- 1996-09-21 CN CN96198113A patent/CN1201385A/zh active Pending
- 1996-09-21 WO PCT/EP1996/004138 patent/WO1997017061A1/fr not_active Ceased
- 1996-09-21 PT PT96931820T patent/PT859595E/pt unknown
- 1996-09-21 IL IL12427997A patent/IL124279A/xx not_active IP Right Cessation
- 1996-09-21 KR KR10-1998-0703316A patent/KR100445940B1/ko not_active Expired - Fee Related
- 1996-09-21 CZ CZ19981366A patent/CZ289143B6/cs not_active IP Right Cessation
- 1996-09-21 SK SK558-98A patent/SK281405B6/sk unknown
- 1996-09-21 US US09/068,326 patent/US6379696B1/en not_active Expired - Lifetime
- 1996-09-21 EP EP96931820A patent/EP0859595B1/fr not_active Expired - Lifetime
- 1996-09-21 AT AT96931820T patent/ATE186209T1/de active
- 1996-09-21 ES ES96931820T patent/ES2141534T3/es not_active Expired - Lifetime
- 1996-09-21 AU AU70859/96A patent/AU716896B2/en not_active Ceased
- 1996-09-21 JP JP51777797A patent/JP2001507331A/ja active Pending
- 1996-09-21 NZ NZ318783A patent/NZ318783A/en unknown
- 1996-09-21 DE DE59603597T patent/DE59603597D1/de not_active Expired - Lifetime
- 1996-09-21 PL PL96326497A patent/PL326497A1/xx unknown
- 1996-11-04 MY MYPI96004590A patent/MY132407A/en unknown
- 1996-11-05 ZA ZA969271A patent/ZA969271B/xx unknown
-
1998
- 1998-05-04 NO NO982006A patent/NO982006L/no not_active Application Discontinuation
- 1998-05-06 MX MX9803563A patent/MX9803563A/es not_active IP Right Cessation
-
2000
- 2000-01-31 GR GR20000400219T patent/GR3032523T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0859595B1 (fr) | 1999-11-03 |
| JP2001507331A (ja) | 2001-06-05 |
| NO982006D0 (no) | 1998-05-04 |
| EP0859595A1 (fr) | 1998-08-26 |
| ES2141534T3 (es) | 2000-03-16 |
| PL326497A1 (en) | 1998-09-28 |
| MX9803563A (es) | 1998-09-30 |
| SK55898A3 (en) | 1998-11-04 |
| CZ289143B6 (cs) | 2001-11-14 |
| CZ136698A3 (cs) | 1998-07-15 |
| WO1997017061A1 (fr) | 1997-05-15 |
| PT859595E (pt) | 2000-04-28 |
| ATE186209T1 (de) | 1999-11-15 |
| NZ318783A (en) | 1999-04-29 |
| IL124279A (en) | 2003-07-06 |
| DE59603597D1 (de) | 1999-12-09 |
| ZA969271B (en) | 1997-06-03 |
| KR100445940B1 (ko) | 2005-09-30 |
| DE19541260A1 (de) | 1997-05-07 |
| AU716896B2 (en) | 2000-03-09 |
| KR19990067320A (ko) | 1999-08-16 |
| GR3032523T3 (en) | 2000-05-31 |
| AU7085996A (en) | 1997-05-29 |
| CN1201385A (zh) | 1998-12-09 |
| NO982006L (no) | 1998-05-04 |
| US6379696B1 (en) | 2002-04-30 |
| MY132407A (en) | 2007-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK281405B6 (sk) | Terapeutický prípravok na transdermálnu aplikáciu účinných látok | |
| EP2521453B1 (fr) | Compositions contenant du vitamin d et une statine destinées au traitement des céphalées migraineuses | |
| US8435556B2 (en) | Transdermal delivery of cannabidiol | |
| JP5184342B2 (ja) | 外用の医薬組成物 | |
| EP3538154B1 (fr) | Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et riociguat | |
| WO1997035576A1 (fr) | Utilisation de l'isoniazide pour le traitement de l'hyperlipoproteinemie | |
| WO2007102241A1 (fr) | Composition pharmaceutique externe | |
| MA26960A1 (fr) | Sels d'un isothiazole-4-carboxamide et leur utilisation comme agent anti-hyperproliferation | |
| MXPA04009819A (es) | Reduccion de crecimiento de vello. | |
| SK7112002A3 (en) | Use of pyrimido-pyrimidine | |
| MXPA01000126A (es) | Compuesto que contiene por lo menos un principio activo que incide en el indice de grasa en la sangre. | |
| US4474748A (en) | Medicaments potentiated with phenyl alkanols | |
| SK73996A3 (en) | Transdermal therapeutical system | |
| WO2008129000A1 (fr) | Dérivés de pyridopyrimidine et leur utilisation dans le traitement des démangeaisons et des troubles associés aux démangeaisons | |
| JP3040427B2 (ja) | 神経痛治療用アスピリン含有軟膏組成物 | |
| EP2570123A1 (fr) | Utilisation de l'alcool 2,4-dichlorobenzylique ayant un effet anesthésique | |
| JPWO2004026297A1 (ja) | 外用剤 | |
| CA2235617C (fr) | Preparation therapeutique pour l'administration transdermique de substances actives | |
| US20190117585A1 (en) | A device for the transdermal delivery of buprenorphine | |
| WO2020033666A1 (fr) | Compositions et procédés de traitement des effets secondaires associés à l'administration d'agents thérapeutiques | |
| Mitani et al. | Fluvastatin, HMG‐CoA Reductase Inhibitor: Antiatherogenic Profiles Through Its Lipid‐Lowering–Dependent and‐Independent Actions | |
| CA2499620A1 (fr) | Preparation externe contenant de l'acide acetylsalicylique pour inhiber la formation de cicatrices cheloidiennes | |
| JP3050917B2 (ja) | 経皮投与基剤組成物とその薬剤組成物 | |
| WO2009080301A1 (fr) | Traitement et prévention des lésions cérébrales ischémiques et des troubles cognitifs cérébrovasculaires, au moyen d'un régime de traitement composé de dipyridamole et d'un bloqueur du récepteur de l'angiotensine ii, chez des patients ayant subi un accident cérébrovasculaire | |
| AU2016228287A1 (en) | Use of anti-bacterial compounds having an anaesthetic effect |